MA40869A - Combinaisons pharmaceutiques de vildagliptine et d'agonistes de ppar - Google Patents

Combinaisons pharmaceutiques de vildagliptine et d'agonistes de ppar

Info

Publication number
MA40869A
MA40869A MA040869A MA40869A MA40869A MA 40869 A MA40869 A MA 40869A MA 040869 A MA040869 A MA 040869A MA 40869 A MA40869 A MA 40869A MA 40869 A MA40869 A MA 40869A
Authority
MA
Morocco
Prior art keywords
vildagliptin
pharmaceutical combinations
ppar agonists
ppar
agonists
Prior art date
Application number
MA040869A
Other languages
English (en)
Inventor
Erdem Ayse Ildes
Mehtap Saydam
Ali Türkyilmaz
Gülay Yelken
Onur Ülgen
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret As filed Critical Sanovel Ilac Sanayi Ve Ticaret As
Publication of MA40869A publication Critical patent/MA40869A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA040869A 2014-10-30 2015-10-27 Combinaisons pharmaceutiques de vildagliptine et d'agonistes de ppar MA40869A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201412671 2014-10-30
TR201413046 2014-11-06

Publications (1)

Publication Number Publication Date
MA40869A true MA40869A (fr) 2017-09-05

Family

ID=54601735

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040869A MA40869A (fr) 2014-10-30 2015-10-27 Combinaisons pharmaceutiques de vildagliptine et d'agonistes de ppar

Country Status (3)

Country Link
EP (1) EP3212185A1 (fr)
MA (1) MA40869A (fr)
WO (1) WO2016066668A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3923932A4 (fr) * 2019-02-13 2022-11-16 Cadila Healthcare Limited Traitement du syndrome des ovaires polykystiques (pcos)
US20220169603A1 (en) * 2019-03-11 2022-06-02 Cadila Healthcare Ltd. Novel salts, crystalline forms and premix of hypolipidemic agent
TR202009946A2 (tr) * 2020-06-25 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve metformi̇n hci i̇çeren bi̇r stabi̇l kombi̇nasyon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0684242B1 (fr) 1993-12-27 1999-05-06 Japan Tobacco Inc. Derive d'isoxazolidinedione et son utilisation
WO1999019313A1 (fr) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
US20060270722A1 (en) * 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
AU2007238522A1 (en) * 2006-01-06 2007-10-25 Novartis Ag Use of vildagliptin for the treatment of diabetes
EP2468268B1 (fr) * 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Composition de combinaison de vildagliptine et de gliclazide
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
WO2013036213A1 (fr) * 2011-09-07 2013-03-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations d'inhibiteur de dpp-iv
US20160107989A1 (en) * 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities

Also Published As

Publication number Publication date
WO2016066668A1 (fr) 2016-05-06
EP3212185A1 (fr) 2017-09-06

Similar Documents

Publication Publication Date Title
HK1244000B (zh) 多環氨基甲酰吡啶酮化合物及其藥物用途
MA49715A (fr) Oligomères et conjugués d'oligomères
DK3142637T3 (da) Keratin treatment formulations and methods
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
ZA202003664B (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
PL3240777T3 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MA46867A (fr) Formulations pharmaceutiques
MA45187A (fr) Combinaisons pharmaceutiques
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
IL250289A0 (en) Antibodies against angiopoietin-like 4 and methods of use
DK3137873T3 (da) Viscometer and methods of use thereof
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
MA40869A (fr) Combinaisons pharmaceutiques de vildagliptine et d'agonistes de ppar
MA42130A (fr) Combinaisons d'opioïdes et de n-acyléthanolamines
MA40868A (fr) Combinaisons pharmaceutiques de sitagliptine et d'agonistes de ppar
FR3016128B1 (fr) Tete de distribution et d'application.
MA40596A (fr) Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
ES1135310Y (es) Rodamiento simplificado y perfeccionado
TH1501006461A (th) อนุพันธ์ของโดลาสแททิน 10 และออริสแททิน (Derivatives of dolastatin 10 and auristatins)
TH1601000571A (th) สารประกอบที่แสดงฤทธิ์ทางการรักษาและวิธีการใช้ของมัน
TH1601002731A (th) อนุพันธ์ของ n-เบนซิล ทริปแทนทริน และวิธีการเตรียมและการนำไปใช้งานของมัน
TH1601000722A (th) สารประกอบชนิดใหม่และองค์ประกอบทางเภสัชกรรมของมันสำหรับการรักษา ซิสติกไฟโบรซิส
TH1601003662A (th) พิเพอริดินิลเตตระไฮโดรควิโนลีนที่ถูกแทนที่ และการใช้งานของพวกมันโดยเป็น แอลฟา-2c อะดรีโนรีเซพเตอร์ แอนทาโกนิสต์
TH1501005057A (th) กระบวนการและสารมัธยันตร์สำหรับเตรียมยา